Nektar Therapeutics – NASDAQ:NKTR

Add to watchlist

$26.76

+25.81

+2719.22%

Market closed

Open in 2 days

-33.17%

month

-33.17%

quarter

+84.63%

year

Market Cap	162.63M
Enterprise value	218.70M

P/E	-0.43
EV/Sales	2.37
EV/EBITDA	-0.67
Price/Sales	1.90
Price/Book	0.47
PEG ratio	-0.01
EPS	-0.92

Revenue	90.16M
EBITDA	-118.94M
Income	-175.84M
Revenue Q/Q	0.20%
Revenue Y/Y	1.50%

Profit margin	-399.98%
Oper. margin	-260.97%
Gross margin	76.5%
EBIT margin	-260.97%
EBITDA margin	-131.92%

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Nektar Therapeutics (NASDAQ:NKTR): Profit margin
Jun 2023	20.49M	-51.12M	-249.39%
Sep 2023	24.14M	-45.83M	-189.85%
Dec 2023	23.88M	-42.07M	-176.17%
Mar 2024	21.63M	-36.80M	-170.07%

Nektar Therapeutics Financials Estimate

Q Y

Nektar Therapeutics (NASDAQ:NKTR): Analyst Estimates
Sep 2025	19M	-48.31M	-254.28%
Oct 2025	22.8M	-30.18M	-132.39%
Dec 2025	22.65M	-32.13M	-141.87%
Mar 2026	19M	-50.01M	-263.23%

Analysts Price target
Financials & Ratios estimates

Nektar Therapeutics (NASDAQ:NKTR): Debt to assets
Jun 2023	494279000	297.32M	60.15%
Sep 2023	442244000	282.87M	63.96%
Dec 2023	398033000	267.04M	67.09%
Mar 2024	396012000	269.30M	68%

Nektar Therapeutics (NASDAQ:NKTR): Cash Flow
Jun 2023	-51.52M	25.17M	18K
Sep 2023	-42.12M	56.41M	-64.92M
Dec 2023	-47.04M	17.38M	12K
Mar 2024	-47.88M	19.25M	42.00M

Nektar Therapeutics alternative data

Social Media

🎓 Academy: How impactful can social media data be in investment decisions

Nektar Therapeutics (NASDAQ:NKTR): Employee count
Aug 2023	216
Sep 2023	216
Oct 2023	216
Nov 2023	216
Dec 2023	216
Jan 2024	216
Feb 2024	216
Mar 2024	137
Apr 2024	137
May 2024	137
Jun 2024	137
Jul 2024	137

Nektar Therapeutics
Hedge Funds Holdings Q1 2023

53.13% -36.82%

of NKTR is owned by hedge funds

114 -92

hedge funds hold NKTR stock

99.43M -69.36M

shares is hold by hedge funds

NKTR hedge funds holdings changes

Nektar Therapeutics
Insider Trading

Nektar Therapeutics (NASDAQ:NKTR): Insider trades (number of shares)
Period	Buy	Sel
Feb 2024	0	36653
May 2024	0	86265
Jun 2024	0	19500
Aug 2024	0	27398
Nov 2024	0	30470
Dec 2024	0	233107

Transaction	Date	Insider	Security	Shares	Price per share	Total value
Sale	24 Dec 2024	WILSON MARK ANDREW officer: Chief Legal Officer officer: Chief Legal Officer	Common Stock	16,560	$0.89	$14,738
Sale	23 Dec 2024	WILSON MARK ANDREW officer: Chief Legal Officer officer: Chief Legal Officer	Common Stock	33,402	$0.9	$30,062
Sale	19 Dec 2024	ZALEVSKY JONATHAN officer: Chief R&..	Common Stock	51,115	$0.94	$48,048
Sale	19 Dec 2024	ZALEVSKY JONATHAN officer: Chief R&..	Common Stock	51,115	$0.94	$48,048
Sale	18 Dec 2024	ROBIN HOWARD W director, officer..	Common Stock	85,035	$0.99	$84,185
Sale	18 Dec 2024	ROBIN HOWARD W director, officer..	Common Stock	85,035	$0.99	$84,185
Sale	17 Dec 2024	ROBIN HOWARD W director, officer..	Common Stock	46,995	$1.01	$47,465
Sale	17 Dec 2024	ROBIN HOWARD W director, officer..	Common Stock	46,995	$1.01	$47,465
Sale	19 Nov 2024	ZALEVSKY JONATHAN officer: Chief R&..	Common Stock	7,785	$1.01	$7,863
Sale	19 Nov 2024	ZALEVSKY JONATHAN officer: Chief R&..	Common Stock	7,785	$1.01	$7,863

NKTR insider trading transactions

Status	Patent	Filling date	Issue date
Grant	Grant Utility: Polymer-sunitinib conjugates Filling date: 7 May 2020 Issue date: 23 Aug 2022	7 May 2020	23 Aug 2022
Grant	Grant Utility: Polymer-des-ethyl sunitinib conjugates Filling date: 9 Jan 2019 Issue date: 9 Aug 2022	9 Jan 2019	9 Aug 2022
Application	Application ADENOSINE 2 RECEPTOR ANTAGONISTS Filling date: 1 May 2020 Issue date: 28 Jul 2022	1 May 2020	28 Jul 2022
Application	Application COMPOSITION COMPRISING A POLYMERIC REAGENT Filling date: 27 Jan 2022 Issue date: 12 May 2022	27 Jan 2022	12 May 2022
Grant	Grant Utility: Immunotherapeutic treatment method using an interleukin-2 receptor beta-selective agonist in combination with adoptive cell transfer therapy Filling date: 1 Mar 2018 Issue date: 3 May 2022	1 Mar 2018	3 May 2022
Application	Application POLYMERIC ALPHA-HYDROXY ALDEHYDE AND KETONE REAGENTS AND CONJUGATION METHOD Filling date: 30 Nov 2021 Issue date: 17 Mar 2022	30 Nov 2021	17 Mar 2022
Application	Application MULTI-ARM POLYMER PRODRUGS Filling date: 24 Nov 2021 Issue date: 17 Mar 2022	24 Nov 2021	17 Mar 2022
Grant	Grant Utility: Conjugates having a degradable linkage and polymeric reagents useful in preparing such conjugates Filling date: 19 May 2020 Issue date: 8 Mar 2022	19 May 2020	8 Mar 2022
Grant	Grant Utility: N-methyl-N-(1-phenyl-2-(1-pyrrolidinyl)ethyl)-2-aminophenylacetamide derivatives agonists for the .kappa. opioid receptor Filling date: 14 May 2019 Issue date: 8 Feb 2022	14 May 2019	8 Feb 2022
Grant	Grant Utility: Polymeric alpha-hydroxy aldehyde and ketone reagents and conjugation method Filling date: 23 Jul 2020 Issue date: 11 Jan 2022	23 Jul 2020	11 Jan 2022

Nektar Therapeutics
Earnings Call Transcripts

Quarter	Transcript
Q1 2024 9 May 2024	Q1 2024 Earnings Call Transcript
Q4 2023 4 Mar 2024	Q4 2023 Earnings Call Transcript
Q3 2023 7 Nov 2023	Q3 2023 Earnings Call Transcript
Q2 2023 8 Aug 2023	Q2 2023 Earnings Call Transcript

NKTR earnings call transcripts

Nektar Therapeutics
Executives

Insider	Age	Compensation
Mr. Howard W. Robin (1953) Chief Executive Officer, Pres & Director	72	$2,240,000
Mr. Gilbert M. Labrucherie J.D. (1972) Senior Vice President, Chief Financial Officer & Chief Operating Officer	53	$1,540,000
Dr. Jonathan Zalevsky (1975) Chief R&D Officer	50	$1,190,000
Mr. John P. Northcott (1978) Senior Vice President & Chief Commercial Officer	47	$1,160,000
Mr. Mark A. Wilson (1972) Senior Vice President, Gen. Counsel & Sec.	53	$780,490

Nektar Therapeutics
Latest News

Saturday, 7 December 2024
12:00	Nektar Therapeutics Announces NKTR-255 Following CD19-directed CAR-T Therapy Enhanced Complete Response Rates in Patients with Relapsed or Refractory Large B-cell Lymphoma at the 66th Annual ASH Meeting	prnewswire.com
Monday, 18 November 2024
15:30	Nektar Therapeutics Presents First Preclinical Data from Novel CSF-1 Program, NKTR-422, at 2024 American College of Rheumatology (ACR) Convergence	prnewswire.com
Thursday, 14 November 2024
09:11	Multiple Catalysts Ahead For Nektar Therapeutics	seekingalpha.com
Friday, 8 November 2024
13:05	Nektar Q3 Loss Narrower Than Expected, Pipeline Development in Focus	zacks.com
Thursday, 7 November 2024
18:41	Nektar Therapeutics (NKTR) Reports Q3 Loss, Tops Revenue Estimates	zacks.com
16:15	Nektar Therapeutics Reports Third Quarter 2024 Financial Results	prnewswire.com
10:15	Nektar and Collaborators Present Late-breaking Results from Phase 2 Study of NKTR-255 for the Treatment of Radiation Induced Lymphopenia in Locally Advanced Non-Small Cell Lung Cancer Patients at Society for Immunotherapy of Cancer (SITC) Annual Meeting	prnewswire.com
Wednesday, 6 November 2024
18:00	Nektar Therapeutics to Participate in Upcoming Investor Conferences	prnewswire.com
Monday, 4 November 2024
13:44	Eczema Drug Developer Nektar Gains Analyst Confidence With 400% Upside Potential	benzinga.com
08:30	Nektar Announces Definitive Agreement with Ampersand Capital Partners to Sell Its Commercial PEGylation Reagent Manufacturing Business in Alabama	prnewswire.com
Thursday, 31 October 2024
18:00	Nektar to Announce Financial Results for the Third Quarter 2024 on Thursday, November 7, 2024, After Close of U.S.-Based Financial Markets	prnewswire.com
Tuesday, 29 October 2024
09:00	Nektar Announces Publication in Nature Communications of Results from Phase 1b Studies of Rezpegaldesleukin in Two Inflammatory Skin Diseases	prnewswire.com
Thursday, 17 October 2024
12:07	Nektar Announces Publication in Blood of Phase 1 Data for Novel IL-15 Agonist NKTR-255 in Combination with Autologous CD19-22 CAR-T Cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia	prnewswire.com
Wednesday, 25 September 2024
03:30	Nektar Therapeutics Announces Multiple Presentations for Rezpegaldesleukin at EADV 2024	prnewswire.com
Tuesday, 3 September 2024
09:00	Nektar Management to Present at Upcoming Investor Conferences	prnewswire.com
Tuesday, 13 August 2024
13:00	What Makes Nektar (NKTR) a New Buy Stock	zacks.com
Saturday, 10 August 2024
09:04	Nektar Therapeutics (NKTR) Q2 2024 Earnings Call Transcript	seekingalpha.com
Friday, 9 August 2024
12:00	Nektar's (NKTR) Q2 Earnings Lag Estimates, Revenues Top	zacks.com
Thursday, 8 August 2024
18:56	Nektar Therapeutics (NKTR) Reports Q2 Loss, Tops Revenue Estimates	zacks.com
16:15	Nektar Therapeutics Reports Second Quarter 2024 Financial Results	prnewswire.com
Thursday, 1 August 2024
18:00	Nektar to Announce Financial Results for the Second Quarter 2024 on Thursday, August 8, 2024, After Close of U.S.-Based Financial Markets	prnewswire.com
Wednesday, 12 June 2024
09:30	Nektar Therapeutics Presents First Preclinical Data on NKTR-0165, a TNFR2 Agonist Antibody Being Developed for the Treatment of Inflammatory Diseases, at EULAR 2024	prnewswire.com
Thursday, 30 May 2024
18:00	Nektar Management to Present at Upcoming Investor Conferences	prnewswire.com
Friday, 10 May 2024
12:35	Nektar's (NKTR) Q1 Earnings and Revenues Surpass Estimates	Zacks Investment Research
Thursday, 9 May 2024
22:40	Nektar Therapeutics, Inc. (NKTR) Q1 2024 Earnings Call Transcript	Seeking Alpha
Thursday, 2 May 2024
18:00	Nektar to Announce Financial Results for the First Quarter 2024 on Thursday, May 9, 2024, After Close of U.S.-Based Financial Markets	PRNewsWire
Wednesday, 3 April 2024
12:31	Nektar (NKTR) Up 7.5% Since Last Earnings Report: Can It Continue?	Zacks Investment Research
Friday, 22 March 2024
14:00	Nektar Management to Present at the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference	PRNewsWire
Wednesday, 6 March 2024
13:35	Nektar (NKTR) Begins Phase IIb Study Rezpeg in Alopecia Areata	Zacks Investment Research
Tuesday, 5 March 2024
11:11	Nektar (NKTR) Q4 Loss Wider Than Expected, Revenue Beat	Zacks Investment Research

Ideas & Opinions

Seeking Alpha 27 Jun 2025

Nektar Therapeutics Scores Big Phase 2b Win With REZPEG
Seeking Alpha 11 Jun 2025

Nektar Therapeutics: 2 Data Readouts For REZPEG 2025 Could Establish Further POC
Seeking Alpha 18 Nov 2022

Nektar Therapeutics: Recovery Seems To Be A Mirage
Seeking Alpha 11 May 2022

Cue Biopharma: A First Assessment
Seeking Alpha 20 Apr 2022

Regenxbio: Is The Ultimate Catalyst Coming?
Seeking Alpha 20 Apr 2022

Iovance: Onward To Approval
Seeking Alpha 13 Nov 2021

Medicenna Therapeutics: Treating Cancer With Immunomodulators
Seeking Alpha 10 Nov 2021

Nektar: The Anatomy Of A Shakedown
Seeking Alpha 29 Sep 2021

Nektar Therapeutics' Short Covering Surges By 200% In 2 Weeks
Seeking Alpha 23 Sep 2021

Nektar Sends Shot Across Bristol Myers Squibb's Bow With Big Pfizer Collaboration

Frequently Asked Questions (FAQ)

What's the price of Nektar Therapeutics stock today?

One share of Nektar Therapeutics stock can currently be purchased for approximately $26.76.
When is Nektar Therapeutics's next earnings date?

Unfortunately, Nektar Therapeutics's (NKTR) next earnings date is currently unknown.
Does Nektar Therapeutics pay dividends?

No, Nektar Therapeutics does not pay dividends.
How much money does Nektar Therapeutics make?

Nektar Therapeutics has a market capitalization of 162.63M and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 2.1% to 90.12M US dollars.
What is Nektar Therapeutics's stock symbol?

Nektar Therapeutics is traded on the NASDAQ under the ticker symbol "NKTR".
What is Nektar Therapeutics's primary industry?

Company operates in the Healthcare sector and Biotechnology industry.
How do i buy shares of Nektar Therapeutics?

Shares of Nektar Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Who are Nektar Therapeutics's key executives?
Nektar Therapeutics's management team includes the following people:
- Mr. Howard W. Robin Chief Executive Officer, Pres & Director(age: 72, pay: $2,240,000)
- Mr. Gilbert M. Labrucherie J.D. Senior Vice President, Chief Financial Officer & Chief Operating Officer(age: 53, pay: $1,540,000)
- Dr. Jonathan Zalevsky Chief R&D Officer(age: 50, pay: $1,190,000)
- Mr. John P. Northcott Senior Vice President & Chief Commercial Officer(age: 47, pay: $1,160,000)
- Mr. Mark A. Wilson Senior Vice President, Gen. Counsel & Sec.(age: 53, pay: $780,490)
How many employees does Nektar Therapeutics have?

As Jul 2024, Nektar Therapeutics employs 137 workers.
When Nektar Therapeutics went public?

Nektar Therapeutics is publicly traded company for more then 31 years since IPO on 3 May 1994.
What is Nektar Therapeutics's official website?

The official website for Nektar Therapeutics is nektar.com.
Where are Nektar Therapeutics's headquarters?

Nektar Therapeutics is headquartered at 455 Mission Bay Boulevard South, San Francisco, CA.
How can i contact Nektar Therapeutics?

Nektar Therapeutics's mailing address is 455 Mission Bay Boulevard South, San Francisco, CA and company can be reached via phone at +41 54825300.

Nektar Therapeutics

nektar.com

Exchange:

NASDAQ

Full time employees:

137

Industry:

Biotechnology

Sector:

Healthcare

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, renal cell carcinoma, muscle-invasive bladder cancer, squamous cell carcinoma of the head and neck, and adjuvant melanoma; phase 2 clinical trial for the treatment of renal cell carcinoma, non-small cell lung cancer, and urothelial cancer; phase 1/2A clinical trial to treat squamous cell carcinoma of the head and neck; phase 1/2 clinical trial for the treatment of solid tumors; and phase 1B clinical trial to treat COVID-19. It is also developing NKTR-358, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 1B clinical trial to treat atopic dermatitis and psoriasis; NKTR-255, an IL-15 receptor agonist, which is in phase 1/2 clinical trial for the treatment of non-Hodgkin's lymphoma and multiple myeloma, and head and neck cancer and colorectal cancer; and NKTR-262, a toll-like receptor agonist that is in phase 1/2 clinical trial to treat solid tumors, as well as various other drug candidates. The company has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Baxalta Incorporated; Eli Lilly and Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. Nektar Therapeutics was incorporated in 1990 and is headquartered in San Francisco, California.

+41 54825300

455 Mission Bay Boulevard South
San Francisco, CA 94158

CIK: 0000906709
ISIN: US6402681083
CUSIP: 640268108